Moleculin Biotech (MBRX)
Market Price (5/3/2026): $2.52 | Market Cap: $7.8 MilSector: Health Care | Industry: Biotechnology
Moleculin Biotech (MBRX)
Market Price (5/3/2026): $2.52Market Cap: $7.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -110% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -140%, 3Y Excs Rtn is -177% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -314% High stock price volatilityVol 12M is 2338% Key risksMBRX key risks include [1] its complete dependence on the clinical success of its lead drug candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -110% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -140%, 3Y Excs Rtn is -177% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -314% |
| High stock price volatilityVol 12M is 2338% |
| Key risksMBRX key risks include [1] its complete dependence on the clinical success of its lead drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Moleculin Biotech (MBRX) stock has lost about 40% since 1/31/2026 because of the following key factors:
1. Dilutive Warrant Exercise and Shareholder Approval.
Moleculin Biotech's stock experienced a significant drop following its announcement on February 19, 2026, of agreements for the immediate exercise of outstanding warrants, which generated approximately $8.3 million in gross proceeds. Crucially, the company also agreed to issue new unregistered warrants to purchase up to 6,367,956 shares of common stock, subject to shareholder approval. This news caused the stock to plummet over 34% in premarket trading on February 19, 2026, due to the substantial potential for dilution of existing shareholders. Shareholders subsequently approved the 6.37 million-share warrant plan on April 15, 2026.
2. Short Cash Runway and Disappointing Financial Results.
The company's full-year 2025 financial results, reported on March 19, 2026, highlighted a challenging financial position. Moleculin reported cash and equivalents of $8.9 million at year-end 2025, and management projected that existing funds, even with the $8.3 million raised in Q1 2026, would only sustain operations until Q3 2026. Furthermore, the company reported an EPS of $(26.06) for Q4 2025, significantly missing the estimated $(11.45). This limited cash runway and a greater-than-expected earnings per share loss contributed to investor concerns regarding financial stability.
Show more
1. Dilutive Warrant Exercise and Shareholder Approval.
Moleculin Biotech's stock experienced a significant drop following its announcement on February 19, 2026, of agreements for the immediate exercise of outstanding warrants, which generated approximately $8.3 million in gross proceeds. Crucially, the company also agreed to issue new unregistered warrants to purchase up to 6,367,956 shares of common stock, subject to shareholder approval. This news caused the stock to plummet over 34% in premarket trading on February 19, 2026, due to the substantial potential for dilution of existing shareholders. Shareholders subsequently approved the 6.37 million-share warrant plan on April 15, 2026.
2. Short Cash Runway and Disappointing Financial Results.
The company's full-year 2025 financial results, reported on March 19, 2026, highlighted a challenging financial position. Moleculin reported cash and equivalents of $8.9 million at year-end 2025, and management projected that existing funds, even with the $8.3 million raised in Q1 2026, would only sustain operations until Q3 2026. Furthermore, the company reported an EPS of $(26.06) for Q4 2025, significantly missing the estimated $(11.45). This limited cash runway and a greater-than-expected earnings per share loss contributed to investor concerns regarding financial stability.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -41.5% change in MBRX stock from 1/31/2026 to 5/2/2026 was primarily driven by a -51.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.29 | 2.51 | -41.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 3 | -51.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MBRX | -41.5% | |
| Market (SPY) | 3.6% | 20.2% |
| Sector (XLV) | -5.8% | 12.8% |
Fundamental Drivers
The -78.4% change in MBRX stock from 10/31/2025 to 5/2/2026 was primarily driven by a -79.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.63 | 2.51 | -78.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 3 | -79.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MBRX | -78.4% | |
| Market (SPY) | 5.5% | -5.5% |
| Sector (XLV) | 1.5% | -14.4% |
Fundamental Drivers
The -90.5% change in MBRX stock from 4/30/2025 to 5/2/2026 was primarily driven by a -93.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.50 | 2.51 | -90.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 3 | -93.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MBRX | -90.5% | |
| Market (SPY) | 30.4% | -4.4% |
| Sector (XLV) | 5.2% | -9.2% |
Fundamental Drivers
The -99.1% change in MBRX stock from 4/30/2023 to 5/2/2026 was primarily driven by a -97.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5022026 | Change |
|---|---|---|---|
| Stock Price ($) | 280.24 | 2.51 | -99.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 3 | -97.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/2/2026| Return | Correlation | |
|---|---|---|
| MBRX | -99.1% | |
| Market (SPY) | 78.7% | -1.1% |
| Sector (XLV) | 14.3% | -5.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MBRX Return | -94% | -43% | -19% | -87% | -92% | -23% | -100% |
| Peers Return | -41% | 1% | -27% | -54% | -21% | -19% | -87% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| MBRX Win Rate | 8% | 25% | 42% | 25% | 33% | 50% | |
| Peers Win Rate | 31% | 42% | 35% | 42% | 43% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MBRX Max Drawdown | -94% | -53% | -64% | -87% | -99% | -41% | |
| Peers Max Drawdown | -44% | -35% | -50% | -59% | -50% | -31% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: KURA, JAZZ, ATNM, CNSP, TVRD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)
How Low Can It Go
| Event | MBRX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -41.7% | -9.5% |
| % Gain to Breakeven | 71.6% | 10.5% |
| Time to Breakeven | 90 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.2% | -33.7% |
| % Gain to Breakeven | 93.1% | 50.9% |
| Time to Breakeven | 23 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -38.0% | -19.2% |
| % Gain to Breakeven | 61.2% | 23.7% |
| Time to Breakeven | 43 days | 105 days |
In The Past
Moleculin Biotech's stock fell -41.7% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 71.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MBRX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -41.7% | -9.5% |
| % Gain to Breakeven | 71.6% | 10.5% |
| Time to Breakeven | 90 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.2% | -33.7% |
| % Gain to Breakeven | 93.1% | 50.9% |
| Time to Breakeven | 23 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -38.0% | -19.2% |
| % Gain to Breakeven | 61.2% | 23.7% |
| Time to Breakeven | 43 days | 105 days |
In The Past
Moleculin Biotech's stock fell -41.7% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 71.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Moleculin Biotech (MBRX)
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
AI Analysis | Feedback
Here are 1-2 brief analogies for Moleculin Biotech (MBRX):
- An early-stage Gilead Sciences or Moderna, focused on developing new drug candidates for difficult cancers and viruses.
- A clinical-stage Bristol Myers Squibb or Novartis, specializing in treatments for highly resistant tumors.
AI Analysis | Feedback
Major products of Moleculin Biotech (MBRX) are its drug candidates:
- Annamycin: A lead drug candidate in Phase 1/2 studies for relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
- WP1066: A flagship immune/transcription modulator in Phase I clinical trial for brain tumors, pediatric brain tumors, pancreatic cancer, and other malignancies.
- WP1220: An analog of WP1066 developed for the topical treatment of cutaneous T-cell lymphoma.
- WP1122: A drug candidate being developed to treat glioblastoma multiforme and COVID-19.
AI Analysis | Feedback
Moleculin Biotech (MBRX) is a clinical-stage pharmaceutical company. At its current stage, the company is focused on the research and development of drug candidates for various diseases, with its lead candidates in Phase 1/2 and Phase I clinical trials. Therefore, Moleculin Biotech does not currently have major customers in the traditional sense of selling commercial products or services to other companies or individuals. Its drug candidates are still in development and have not yet reached commercialization.
AI Analysis | Feedback
nullAI Analysis | Feedback
Walter V. Klemp, Chairman and Chief Executive OfficerMr. Klemp is a co-founder of Moleculin Biotech, Inc. and has served as Chairman and Chief Executive Officer since July 2015. He is a serial entrepreneur with a history of successful exits. He co-founded Soliton, Inc., took it public on Nasdaq in 2018, and oversaw its acquisition by AbbVie in December 2021 for approximately $550 million. From 2011 to 2020, he served as CEO and then Executive Chairman of Soliton. Previously, he was President and CEO of Zeno Corporation (2004-2011) and the Founder, CEO, and Chairman of Drypers Corporation (1987-2000), a publicly traded multinational consumer products company that was ranked #1 on the INC 500 List.
Jonathan P. Foster, Executive Vice President and Chief Financial Officer
Mr. Foster joined Moleculin in August 2016 and brings over 30 years of financial experience. From 2012, he served as Executive Vice President and CFO of InfuSystem Holdings, Inc., an NYSE MKT listed company, where he led significant financial improvements and refinancings that increased the company's Enterprise Value by over 50%. He also served as Executive Vice President and CFO of Drypers Corporation from 1996 to 2000, working alongside Walter Klemp. From July 2018 to December 2020, Mr. Foster was a board member and committee chairman for Soliton, Inc., before its acquisition by AbbVie.
Donald H. Picker, PhD, Chief Scientific Officer
Dr. Picker has served as Moleculin's Chief Scientific Officer since August 2017, after holding roles as Chief Operating Officer (2015-2017) and President (2016-2017). He is a co-founder of the company, and his employment is on a part-time basis.
Waldemar Priebe, PhD, Head of Scientific Advisory Board
Dr. Priebe is a co-founder and founding scientist of Moleculin Biotech and serves as the head of its Scientific Advisory Board. He is a Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, where he led the discovery of the molecules that form the basis for Moleculin's lead drug candidates. Dr. Priebe has founded or been a founding scientist at several successful biotechnology firms, including CNS Pharmaceuticals, Aronex Pharmaceuticals, Houston Pharmaceuticals, Reata Pharmaceuticals, and IntertechBio. He has been instrumental in advancing several drugs, with four currently in clinical development, and is the co-founder of six biotechnology companies in the US.
Wolfram C. M. Dempke, MD, PhD, MBA, Medical Advisor
Dr. Dempke serves as a Medical Advisor to Moleculin. He has a distinguished 30-year career in oncology, hematology, and academia, with substantial contributions to clinical developments in ovarian cancer, lung cancer, leukemias, and lymphomas. His prior roles include External Expert at Novartis Oncology Global Clinical Development, Head, Global Medical Affairs for EUSA Pharma, and Executive Medical Director for Kyowa Kirin Pharmaceutical Development Ltd., where he was responsible for global clinical development (Phase 1-3) in leukemias and lymphomas.
AI Analysis | Feedback
Key Business Risks for Moleculin Biotech (MBRX)
- Clinical Trial Outcomes and Drug Development Risk: As a clinical-stage pharmaceutical company, Moleculin Biotech's future is predominantly dependent on the successful outcomes of its drug candidates, particularly its lead candidate, Annamycin, currently in the pivotal Phase 3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML). A disappointing or ambiguous data readout from this crucial trial could significantly diminish the company's value, as it currently lacks commercial revenues to offset such setbacks. Clinical failures, including insufficient efficacy or unexpected safety concerns, can occur at any stage of development, potentially leading to increased costs, delays, or even project termination.
- Financial Health, Funding, and Dilution Risk: Moleculin Biotech faces significant financial challenges characterized by a substantial "cash burn" primarily driven by research and development expenses. As a pre-revenue company, it relies heavily on equity offerings to fund its operations, resulting in a tight cash runway and negative shareholder equity. This necessitates frequent capital raises, which in turn lead to the dilution of existing shareholders. The company has faced Nasdaq compliance concerns and a potential bankruptcy risk within 12 months without additional financing.
- Regulatory Approval Risk: Even if clinical trials yield positive results, Moleculin Biotech's drug candidates must successfully navigate complex regulatory approval processes with agencies such as the FDA and European regulators. These regulatory bodies may require additional trials or impose restrictions on product labeling, which could delay market entry or limit commercial potential. The pharmaceutical industry operates under a highly scrutinized and evolving regulatory framework, where compliance risks are substantial.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for Moleculin Biotech's main products are as follows:
Annamycin
- Relapsed or Refractory Acute Myeloid Leukemia (AML): The global acute myeloid leukemia treatment market was valued at approximately USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. North America dominated this market with a 37.6% share in 2024, with the U.S. accounting for 90.9% of the North American market.
- Cancers Metastasized to the Lungs: The global metastatic non-small cell lung cancer market size was estimated at USD 18.50 billion in 2025 and is predicted to increase to approximately USD 50.30 billion by 2035. For metastatic lung adenocarcinoma specifically, the global market size was valued at USD 4.90 billion in 2024 and is projected to reach USD 9.29 billion by 2030. North America secured the largest market share in 2025 for metastatic non-small cell lung cancer (45%) and in 2024 for metastatic lung adenocarcinoma (39.5%).
WP1066
- Brain Tumors (including pediatric brain tumors): The global brain tumor treatment market was estimated at USD 3.58 billion in 2025 and is predicted to increase to approximately USD 7.21 billion by 2035. North America is projected to lead this market, holding a 38.3% share in 2025. The U.S. brain tumor treatment market was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.85 billion by 2035. Separately, the global pediatric brain tumors market is estimated to be valued at USD 1.66 billion in 2025 and is expected to reach USD 2.68 billion by 2032. The USA Pediatric Brain Tumor Market was estimated at USD 0.76 billion in 2024 and is projected to reach USD 1.08 billion by 2030.
- Pancreatic Cancer: The global pancreatic cancer treatment market was valued at USD 6.4 billion in 2024 and is expected to reach USD 12.4 billion by 2030. The U.S. pancreatic cancer treatment market size was estimated at USD 1.75 billion in 2025 and is projected to reach approximately USD 5.46 billion by 2035. North America dominated the global market with a share of 39.27% in 2024.
WP1220
- Cutaneous T-cell Lymphoma (CTCL): The global cutaneous T-cell lymphoma (CTCL) market is projected to grow from USD 1.3 billion in 2024 to USD 2.5 billion by 2030. In the 7MM (United States, EU4, UK, and Japan), the market size was approximately USD 1,042 million in 2025 and is projected to reach USD 1,622 million by 2034. The United States accounted for the highest CTCL market size in the 7MM, approximately 70% in 2024.
WP1122
- Glioblastoma Multiforme (GBM): The global glioblastoma multiforme treatment market was valued at USD 3.6 billion in 2024 and is expected to grow to USD 8.3 billion by 2034. The U.S. glioblastoma multiforme treatment market accounted for USD 1.4 billion in 2024. North America held the largest share of 40.01% of the global market in 2025.
- COVID-19: The global COVID-19 therapeutics market size was approximately USD 32542.5 million in 2025. North America held the major market share, more than 40% of the global revenue, with a market size of USD 13017.00 million in 2025.
AI Analysis | Feedback
For Moleculin Biotech (MBRX), a clinical-stage pharmaceutical company with no current commercial revenue, the expected drivers of future revenue growth over the next 2-3 years are intrinsically linked to the successful advancement and potential commercialization of its drug candidates. Analysts currently project no revenue for the company through at least 2025 and 2026.
The primary drivers of potential future revenue growth include:
- Successful Advancement and Potential Regulatory Approval of Annamycin for Acute Myeloid Leukemia (AML): Annamycin, Moleculin's lead drug candidate, is in a pivotal Phase 2B/3 MIRACLE trial for relapsed or refractory AML. Key milestones expected within the next 2-3 years include data readouts from Part A of the trial in Q1 and Q3 2026, the commencement of Part B in the second half of 2026, and the initiation of a rolling New Drug Application (NDA) submission by late 2028. Annamycin has also been granted Fast Track Status and Orphan Drug Designation by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for AML, which could facilitate expedited development and review.
- Expansion of Annamycin into New Indications, such as Pancreatic Cancer: Beyond AML, Moleculin is strategically broadening Annamycin's potential applications. An investigator-initiated Phase 1B/2 trial for advanced pancreatic cancer, utilizing Annamycin, is anticipated to begin in the second half of 2026. Successful progression in new indications like pancreatic cancer would significantly expand the drug's addressable market and future revenue potential.
- Progression of WP1066 in Clinical Trials for Brain Tumors: WP1066, an immune/transcription modulator, is being developed for brain tumors. The ongoing Phase 2 Glioblastoma Multiforme (GBM) trial at Northwestern University is expected to continue in Q1 2026, with a pediatric brain tumor trial at Emory University planned for the second half of 2026. Positive clinical outcomes from these trials could lead to further development stages and eventual commercialization.
- Advancement of WP1122 in Clinical Development for Glioblastoma Multiforme (GBM): WP1122, another of Moleculin's drug candidates, holds Fast Track and Orphan Drug Designation from the FDA for the treatment of GBM. The allowance for a Phase 1 study by the FDA indicates progress, and the initiation and successful completion of clinical trials for WP1122 for GBM represent a future revenue opportunity.
AI Analysis | Feedback
```htmlShare Issuance
- In June 2025, Moleculin Biotech announced a public offering of common stock and Series E warrants, expected to generate approximately $5.9 million in gross proceeds.
- The number of shares outstanding increased to 51 million in Q3 2025, marking a 68.1% rise from the previous quarter.
- A 1-for-25 reverse stock split was effected on December 1, 2025, reducing the outstanding common stock from approximately 51.7 million shares to about 2.1 million shares.
Capital Expenditures
- Moleculin Biotech reported $0 in capital expenditures for Q3 2025.
- Free cash flow was -$7.2 million in Q3 2025, representing cash available after capital expenditures.
- Operating earnings demonstrate weak coverage of $112,000 in depreciation charges, suggesting high capital intensity and potential reinvestment needs despite recent zero capital expenditures.
Trade Ideas
Select ideas related to MBRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.83 |
| Mkt Cap | 0.0 |
| Rev LTM | 1 |
| Op Inc LTM | -25 |
| FCF LTM | -23 |
| FCF 3Y Avg | -21 |
| CFO LTM | -23 |
| CFO 3Y Avg | -18 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 20.3% |
| Rev Chg 3Y Avg | 5.3% |
| Rev Chg Q | -28.9% |
| QoQ Delta Rev Chg LTM | 0.0% |
| Op Inc Chg LTM | -0.8% |
| Op Inc Chg 3Y Avg | -3.3% |
| Op Mgn LTM | -707.3% |
| Op Mgn 3Y Avg | 15.2% |
| QoQ Delta Op Mgn LTM | 63.2% |
| CFO/Rev LTM | -504.8% |
| CFO/Rev 3Y Avg | 31.5% |
| FCF/Rev LTM | -509.7% |
| FCF/Rev 3Y Avg | 29.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | 11.5 |
| P/Op Inc | -0.6 |
| P/EBIT | -1.1 |
| P/E | -1.6 |
| P/CFO | -0.8 |
| Total Yield | -71.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -55.7% |
| D/E | 0.0 |
| Net D/E | -1.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.1% |
| 3M Rtn | -11.7% |
| 6M Rtn | -26.7% |
| 12M Rtn | -55.0% |
| 3Y Rtn | -85.1% |
| 1M Excs Rtn | -3.5% |
| 3M Excs Rtn | -15.9% |
| 6M Excs Rtn | -33.4% |
| 12M Excs Rtn | -83.8% |
| 3Y Excs Rtn | -163.2% |
Price Behavior
Price Behavior
| Market Price | $2.51 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/02/2016 | |
| Distance from 52W High | -90.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.35 | $7.75 |
| DMA Trend | down | down |
| Distance from DMA | 7.0% | -67.6% |
| 3M | 1YR | |
| Volatility | 111.8% | 2,347.1% |
| Downside Capture | 2.71 | -0.58 |
| Upside Capture | 142.54 | -348.02 |
| Correlation (SPY) | 19.4% | -4.1% |
MBRX Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.51 | 0.70 | 1.48 | -13.35 | -8.17 | -0.97 |
| Up Beta | -0.31 | -0.78 | 0.03 | -4.62 | -1.81 | 0.43 |
| Down Beta | 8.91 | 2.31 | -0.42 | 28.10 | 7.87 | 3.63 |
| Up Capture | 27% | 101% | 150% | -184% | -69% | -7% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 22 | 33 | 59 | 118 | 329 |
| Down Capture | -701% | 89% | 320% | -1137% | -209% | 100% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 7 | 17 | 27 | 61 | 127 | 401 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MBRX | |
|---|---|---|---|---|
| MBRX | -90.6% | 2,337.7% | 0.90 | - |
| Sector ETF (XLV) | 5.2% | 16.0% | 0.13 | -9.2% |
| Equity (SPY) | 30.6% | 12.5% | 1.88 | -4.4% |
| Gold (GLD) | 39.5% | 27.2% | 1.20 | 1.3% |
| Commodities (DBC) | 51.5% | 17.9% | 2.20 | 0.6% |
| Real Estate (VNQ) | 13.1% | 13.5% | 0.67 | -8.4% |
| Bitcoin (BTCUSD) | -17.1% | 42.2% | -0.33 | -11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MBRX | |
|---|---|---|---|---|
| MBRX | -71.8% | 1,052.2% | 0.37 | - |
| Sector ETF (XLV) | 5.0% | 14.6% | 0.17 | -3.8% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | -0.1% |
| Gold (GLD) | 20.5% | 17.9% | 0.94 | 1.2% |
| Commodities (DBC) | 14.3% | 19.1% | 0.61 | 0.8% |
| Real Estate (VNQ) | 3.5% | 18.8% | 0.09 | -1.4% |
| Bitcoin (BTCUSD) | 7.7% | 56.2% | 0.35 | -3.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MBRX | |
|---|---|---|---|---|
| MBRX | -65.6% | 755.5% | 0.27 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | -1.0% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 1.4% |
| Gold (GLD) | 13.6% | 15.9% | 0.71 | 1.0% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 1.2% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 0.2% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | -1.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/19/2026 | -1.0% | 19.7% | 16.3% |
| 8/13/2025 | 1.9% | -10.0% | -43.2% |
| 3/24/2025 | -2.8% | -4.6% | -3.7% |
| 11/12/2024 | 5.2% | 0.4% | 5.6% |
| 8/14/2024 | 6.4% | 9.4% | 3.4% |
| 3/22/2024 | -8.0% | -0.6% | -19.4% |
| 11/13/2023 | 6.7% | 9.3% | -5.6% |
| 8/11/2023 | -2.0% | -8.6% | -36.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 6 |
| # Negative | 10 | 9 | 11 |
| Median Positive | 6.4% | 9.3% | 7.2% |
| Median Negative | -3.3% | -8.6% | -14.6% |
| Max Positive | 11.1% | 19.7% | 54.3% |
| Max Negative | -8.4% | -14.6% | -43.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/18/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/22/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/19/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Financing Proceeds | 8.30 Mil | ||||||
Prior: Q2 2025 Earnings Reported 8/13/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2025 Clinical Sites | 20 | ||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.